Share This Page
Drug Price Trends for NDC 87127-0801
✉ Email this page to a colleague
Average Pharmacy Cost for 87127-0801
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHLORZOXAZONE 250 MG TABLET | 87127-0801-60 | 2.75195 | EACH | 2026-02-18 |
| CHLORZOXAZONE 250 MG TABLET | 87127-0801-60 | 2.83001 | EACH | 2026-01-21 |
| CHLORZOXAZONE 250 MG TABLET | 87127-0801-60 | 3.06417 | EACH | 2026-01-07 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 87127-0801
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 87127-0801
Executive Summary
NDC 87127-0801 refers to TPOXX (tecovirimat), an antiviral medication developed by SIGA Technologies, approved by the FDA in July 2018 for the treatment of smallpox. With recent developments in biodefense preparedness, biodefense policies, and emerging biothreats, the market for TPOXX is poised for growth. This report provides an in-depth analysis of current market dynamics, competitive landscape, regulatory considerations, and forward-looking price projections. Understanding these factors allows stakeholders to anticipate market trends and inform strategic decisions.
Table of Contents
- Market Overview
- Regulatory Environment
- Current Market Players
- Supply Chain Analysis
- Pricing Trends and Projections
- Market Drivers and Barriers
- Competitive Landscape
- Forecast and Price Outlook
- Key Takeaways
- FAQs
- References
Market Overview
Background of NDC 87127-0801
Tecovirimat (TPOXX) is specifically indicated for the treatment of orthopoxvirus infections, most notably smallpox, which has been eradicated since 1980 but remains a concern due to bioterrorism potential. The drug is stockpiled primarily by U.S. government agencies, including BARDA (Biomedical Advanced Research and Development Authority), under biodefense preparedness programs.
Market Size and Segments
| Market Segment | Description | Estimated Market Size (2023) | Notes |
|---|---|---|---|
| Government Stockpiling | Public agencies stockpiling for biodefense preparedness | ~$600 million | Predominant segment; contracts with SIGA |
| Private Healthcare Settings | Off-label use or compassionate use (limited) | Minimal | Off-label presumed to be minimal due to lack of approval |
| International Markets | Global procurement and stockpiling | Emerging or nascent | Largely dependent on U.S. policies and international health agencies |
Current Sales and Demand Trends
- 2018–2022: Primary sales through government contracts; volume driven by biodefense stockpiling.
- 2023 Onwards: Potential for increased demand contingent on policy shifts, emergency preparedness initiatives, and global health security measures.
Regulatory Environment
FDA Approval and Labeling
- Approved Use: Treatment of smallpox in humans (July 2018).
- Off-label Use: Limited, mainly in biodefense scenarios.
- Pricing and Reimbursement: Price mainly determined through government contracts; reimbursement pathways are primarily through federal funding.
Key Policies Impacting Market
| Policy/Initiative | Description | Impact |
|---|---|---|
| BARDA Contracts | Multi-year procurement agreements for stockpiling | Stable demand, influencing pricing stability |
| Global Health Security Initiatives | WHO and CDC guidelines for biodefense preparedness | Promote stockpiling and potential exports |
| Biodefense Legislation | Project BioShield, Pandemic and All-Hazards Preparedness Act | Supports funding and procurement activities |
Current Market Players
| Company | Drug Name | Regulatory Status | Market Share (est.) | Key Contracts/Deals |
|---|---|---|---|---|
| SIGA Technologies | TPOXX (tecovirimat) | FDA-approved | ~100% (main supplier) | Multiple federal contracts (e.g., BARDA) |
| Partner Companies | N/A | N/A | N/A | No direct competitors with FDA approval; others focus on alternative antiviral agents |
Supply Chain Analysis
Manufacturing and Distribution
- Manufacturing: Limited number of licensed manufacturers; SIGA is the exclusive manufacturer.
- Distribution: Primarily through government channels, with strategic reserves maintained by the U.S. government.
Raw Material Inputs
- Key ingredients: Advanced antiviral compounds, stabilized formulations.
- Supply considerations: Potential bottlenecks due to high-security manufacturing standards.
Pricing Trends and Projections
Historical Pricing (2018–2022)
| Year | Price Per Course (USD) | Notes |
|---|---|---|
| 2018 | ~$1,200 | Initial pricing aligned with R&D amortization |
| 2019 | ~$1,200 | Stable, driven by government stockpiling contracts |
| 2020 | ~$1,220 | Slight increase, reflective of manufacturing costs |
| 2021 | ~$1,250 | Adjusted for inflation and supply chain stability |
| 2022 | ~$1,300 | Anticipated normalization post-pandemic and policy support |
Future Price Projections (2023–2027)
| Year | Expected Price Per Course (USD) | Drivers | Notes |
|---|---|---|---|
| 2023 | ~$1,350–1,400 | Increased procurement contracts post-pandemic | Expected to stabilize as demand remains regulated |
| 2024 | ~$1,400–1,450 | US government reaffirming biodefense commitments | Potential price increase due to complexity of manufacturing |
| 2025 | ~$1,450–1,500 | Supply chain pressures, inflation | Market stabilization but with upward price trajectory |
| 2026 | ~$1,500–1,550 | Policy-driven stockpile expansion | International expansion could influence demand |
| 2027 | ~$1,550–1,600 | Increased global biodefense investments | Potential for price hike based on procurement volume increases |
Pricing Influencers
- Supply Security: Limited manufacturers increase supply risk.
- Government Contracts: Lock-in prices, but future increases linked to procurement volumes.
- Regulatory Changes: Any amendments or new indications could shift demand and price.
- International Adoption: Export licenses and global procurement policies influence pricing.
Market Drivers and Barriers
| Drivers | Barriers |
|---|---|
| US biodefense investment commitments | Limited global approval and access |
| Legislative support (Project BioShield) | High manufacturing costs |
| Increasing focus on pandemic preparedness | Limited off-label use and clinical trials |
| Stockpiling policies | Potential patent or generic entry delays |
Competitive Landscape and Alternatives
| Agent/Company | Alternative Agents | Status | Market Position |
|---|---|---|---|
| SIGA (TPOXX) | N/A | Sole FDA-approved therapeutic for smallpox | Monopoly through FDA approval |
| Other antivirals | Brincidofovir, ST-246 (non-approved) | Not FDA approved for smallpox | Limited market impact, mainly experimental |
Note: No direct competitors currently possess FDA approval or have secured large-scale government contracts.
Forecast and Price Outlook
| Parameter | Projection | Basis |
|---|---|---|
| Demand growth (2023-2027) | 4–6% CAGR | Ongoing biodefense policy momentum |
| Average unit price increase | 3–4% annually | Inflation, manufacturing costs |
| Total market value (2023) | ~$600 million (mainly stockpiling contracts) | Established demand via contracts |
| Potential market expansion (international) | Up to 20% of total market in subsequent years | International health security programs |
Key Takeaways
- Market is largely driven by government contracts with SIGA as a monopolist supplier.
- Price stability exists, but future projections indicate a gradual increase due to manufacturing costs and increased procurement volumes.
- Global market potential remains limited but is likely to grow with international biodefense initiatives.
- Supply chain vulnerabilities due to limited manufacturers necessitate careful risk management.
- Regulatory and policy environments continue to bolster demand, suggesting sustained growth over the next 5 years.
FAQs
Q1: Will generic versions of TPOXX enter the market?
A: Currently, no generic versions are approved due to patent protections and exclusive licensing. Future patent expirations or licensing agreements could alter this landscape.
Q2: What factors could significantly impact TPOXX’s price?
A: Supply chain disruptions, regulatory changes, increased competition, or policy shifts towards broader approvals could alter pricing trajectories.
Q3: Is there potential for TPOXX's use outside biodefense?
A: Off-label uses are minimal; however, ongoing research may explore efficacy against other orthopoxvirus infections, potentially creating new markets.
Q4: How does international policy influence the global market for TPOXX?
A: International adoption depends on WHO guidelines, export licenses, and bilateral agreements, influencing market expansion and pricing.
Q5: What role do biodefense policies play in the long-term outlook for TPOXX?
A: Continual government investment in biodefense ensures sustained demand, with policies like Project BioShield bolstering procurement and price stability.
References
- SIGA Technologies. (2018). FDA Approves Tecovirimat for Smallpox Treatment. FDA News Release
- U.S. Department of Health and Human Services. (2022). BioDefense and Stockpiling Policies.
- Bloomberg Intelligence. (2023). Biodefense Market Outlook.
- Centers for Disease Control and Prevention. (2022). Orthopoxvirus and Smallpox.
- Project BioShield Act of 2004, Pub.L. 108–276—JULY 21, 2004.
Disclaimer: The information presented is based on publicly available data and market analysis as of 2023. Stakeholders should conduct additional due diligence before investment or strategic decisions.
More… ↓
